168 related articles for article (PubMed ID: 36377252)
1. Clinical implementation of integrated molecular-morphologic risk prediction for meningioma.
Hielscher T; Sill M; Sievers P; Stichel D; Brandner S; Jones DTW; von Deimling A; Sahm F; Maas SLN
Brain Pathol; 2023 May; 33(3):e13132. PubMed ID: 36377252
[TBL] [Abstract][Full Text] [Related]
2. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.
Maas SLN; Stichel D; Hielscher T; Sievers P; Berghoff AS; Schrimpf D; Sill M; Euskirchen P; Blume C; Patel A; Dogan H; Reuss D; Dohmen H; Stein M; Reinhardt A; Suwala AK; Wefers AK; Baumgarten P; Ricklefs F; Rushing EJ; Bewerunge-Hudler M; Ketter R; Schittenhelm J; Jaunmuktane Z; Leu S; Greenway FEA; Bridges LR; Jones T; Grady C; Serrano J; Golfinos J; Sen C; Mawrin C; Jungk C; Hänggi D; Westphal M; Lamszus K; Etminan N; Jungwirth G; Herold-Mende C; Unterberg A; Harter PN; Wirsching HG; Neidert MC; Ratliff M; Platten M; Snuderl M; Aldape KD; Brandner S; Hench J; Frank S; Pfister SM; Jones DTW; Reifenberger G; Acker T; Wick W; Weller M; Preusser M; von Deimling A; Sahm F;
J Clin Oncol; 2021 Dec; 39(34):3839-3852. PubMed ID: 34618539
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
4. Mutational signature of extracranial meningioma metastases and their respective primary tumors.
Biczok A; Thorsteinsdottir J; Karschnia P; Ruf VC; Tonn JC; Herms J; Schichor C; Dorostkar MM
Acta Neuropathol Commun; 2023 Jan; 11(1):12. PubMed ID: 36641486
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Nassiri F; Mamatjan Y; Suppiah S; Badhiwala JH; Mansouri S; Karimi S; Saarela O; Poisson L; Gepfner-Tuma I; Schittenhelm J; Ng HK; Noushmehr H; Harter P; Baumgarten P; Weller M; Preusser M; Herold-Mende C; Tatagiba M; Tabatabai G; Sahm F; von Deimling A; ; Zadeh G; Aldape KD
Neuro Oncol; 2019 Jul; 21(7):901-910. PubMed ID: 31158293
[TBL] [Abstract][Full Text] [Related]
6. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
[TBL] [Abstract][Full Text] [Related]
7. WHO grade and pathological markers of meningiomas: Clinical and prognostic role.
Franca RA; Della Monica R; Corvino S; Chiariotti L; Del Basso De Caro M
Pathol Res Pract; 2023 Mar; 243():154340. PubMed ID: 36738518
[TBL] [Abstract][Full Text] [Related]
8. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma.
Mirian C; Grell K; Juratli TA; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Jensen LR; Schackert G; Broholm H; Scheie D; Cahill DP; Brastianos PK; Skjøth-Rasmussen J; Fugleholm K; Ziebell M; Munch TN; Kristensen BW; Mathiesen T
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12773. PubMed ID: 34799864
[TBL] [Abstract][Full Text] [Related]
9. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
11. Pediatric meningioma: a clinicopathologic and molecular study with potential grading implications.
Toland A; McNulty SN; Pekmezci M; Evenson M; Huntoon K; Pierson CR; Boue DR; Perry A; Dahiya S
Brain Pathol; 2020 Nov; 30(6):1134-1143. PubMed ID: 32716568
[TBL] [Abstract][Full Text] [Related]
12. Infarction with associated pseudosarcomatous changes mimics anaplasia in otherwise grade I meningiomas.
Bale TA; Benhamida J; Roychoudury S; Villafania L; Wrzolek MA; Bouffard JP; Bapat K; Ladanyi M; Rosenblum MK
Mod Pathol; 2020 Jul; 33(7):1298-1306. PubMed ID: 32047229
[TBL] [Abstract][Full Text] [Related]
13. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
14. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
Guyot A; Duchesne M; Robert S; Lia AS; Derouault P; Scaon E; Lemnos L; Salle H; Durand K; Labrousse F
J Neurooncol; 2019 Dec; 145(3):449-459. PubMed ID: 31729637
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
18. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
19. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
20. A deep learning radiomics model for preoperative grading in meningioma.
Zhu Y; Man C; Gong L; Dong D; Yu X; Wang S; Fang M; Wang S; Fang X; Chen X; Tian J
Eur J Radiol; 2019 Jul; 116():128-134. PubMed ID: 31153553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
